Preclinical Development
CIRM’s Preclinical Development grant funds advanced preclinical research to move stem cell and genetic therapies toward FDA IND clearance and clinical trial readiness.
Funder: California Institute for Regenerative Medicine
Due Dates: October 8, 2026 (PDEV application submission deadline, 2 PM PT)
Funding Amounts: Up to $13,000,000 per award | Award duration up to 5 years
Summary: Funds preclinical research to advance stem cell-based and genetic therapies toward FDA IND clearance and clinical trial readiness.
Key Information: Applicant must be a California Organization; co-funding required for for-profits/partnered non-profits.
Description
The Preclinical Development (PDEV) program, offered by the California Institute for Regenerative Medicine (CIRM), is designed to accelerate the advancement of stem cell-based and genetic therapies from the laboratory to clinical application. The program supports projects completing preclinical studies, obtaining FDA Investigational New Drug (IND) clearance, and initiating clinical trial startup activities. Emphasis is placed on therapies with transformative clinical potential and projects that address significant barriers to patient access. CIRM provides not only funding but also expert guidance, access to specialized networks, and a collaborative knowledge-sharing environment to maximize the likelihood of project success.
